What is the FDA saying about BPC-157 and KPV?
If you have been following the news on bpc-157, you know things are moving fast. As of September 2026, its regulatory status is evolving. It was previously placed in FDA Category 2, which is a list of substances that may present significant safety risks.
In July 2026, the Pharmacy Compounding Advisory Committee — a group that gives the FDA advice — reviewed BPC-157 for possible inclusion on the 503A Bulks List. The FDA has identified potential safety concerns here, including immunogenicity (the risk of your immune system reacting to the drug) and a lack of human safety data.
KPV is in a similar boat. It was moved into Category 2, then removed when the nomination was withdrawn. However, it was also reviewed by the advisory committee in July 2026. The FDA still has concerns about the limited information available regarding how KPV affects humans.
Is Semaglutide still in short supply?
The national shortage for semaglutide has stabilized. The FDA has ended the period where certain compounding rules were relaxed due to the shortage. This means compounding pharmacies are back to following strict rules about not making copies of commercially available drugs.
There are also some safety signals to keep an eye on. While weight loss results in the STEP 1 trial showed a 14.9% reduction, real-world data in the FAERS database (a system that tracks side effects) shows common issues like nausea and vomiting. More serious emerging signals under evaluation include:
- NAION: A rare eye condition currently under review by the EMA as of January 2025.
- Pulmonary Aspiration: A risk of food or liquid entering the lungs during anesthesia, added to the Ozempic label in 2025.
- Delayed Gastric Emptying: When food stays in your stomach longer than it should.
Why are some peptides in Category 2?
You might see several compounds listed as Category 2. This usually means the FDA has specific concerns about safety or how the substance is made.
- GHRP-2 and GHRP-6 are both in Category 2 as of September 2023 due to immunogenicity concerns.
- Melanotan II is listed due to multiple serious adverse events (harmful side effects).
- LL-37 and PEG-MGF were also placed in this category in September 2023.
- MK-677 is currently in Category 2 for both 503A and 503B facilities.
Next steps for your health
This is a great one to bring up with your doctor. Because laws and safety data change quickly, you should work with a professional who stays current on these records.
You can find peptide-experienced physicians in our Find a Doctor directory. If you are looking for specific local options, you can also search for peptide therapy near me to see who is available. A professional can help you understand how to find a peptide prescriber who follows these latest safety standards.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.